Welcome to our dedicated page for Opthea news (Ticker: OPT), a resource for investors and traders seeking the latest updates and insights on Opthea stock.
Opthea Ltd (ASX:OPT) is a clinical-stage biopharmaceutical company developing innovative therapies for retinal diseases, with its lead candidate OPT-302 targeting VEGF-C and VEGF-D pathways. This page provides investors and stakeholders with timely updates on clinical trial progress, regulatory milestones, and corporate developments.
Access comprehensive coverage of Opthea's press releases, including updates on phase 1/2a trials for wet AMD treatment, intellectual property advancements, and strategic collaborations. Our curated news feed ensures you stay informed about key events influencing the company's trajectory in ocular therapeutics.
Discover updates across multiple categories including clinical research breakthroughs, financial results, patent filings, and executive leadership announcements. All content is verified through primary sources to maintain accuracy and compliance with financial disclosure standards.
Bookmark this page for streamlined access to Opthea's latest developments. Check back regularly for real-time updates on this pioneering biotechnology firm's progress in addressing unmet needs in retinal disease treatment.
Opthea (ASX/NASDAQ: OPT) has announced a capital raising initiative to secure up to A$227.3 million (US$150 million). This includes a A$10 million placement and a A$217.3 million Accelerated Non-Renounceable Entitlement Offer (ANREO). The raised funds will support the Phase 3 clinical trials of sozinibercept for wet AMD, with topline data expected in early and mid-2025. The capital will also progress chemistry, manufacturing, and Biologics License Application (BLA) preparations for FDA approval. The offer price is set at A$0.40 per share, representing discounts to recent trading prices. MST Financial Services will act as the placement agent and lead manager, with BofA Securities and Leerink Partners advising the transactions.
Opthea, a clinical-stage biopharmaceutical company, will present at the Clinical Trials at the Summit (CTS) Meeting in Park City, Utah, on June 8, 2024. Key presentations will include discussions by CEO Frederic Guerard, and scientific presentations by Megan Baldwin and Julie Clark, focusing on the sozinibercept (OPT-302) clinical trial program for wet age-related macular degeneration (wet AMD). The CTS meeting is a significant event that gathers global experts to discuss the latest clinical trials and advancements in vitreoretinal care.
Opthea announced the completion of enrollment for its pivotal Phase 3 clinical program with sozinibercept for wet age-related macular degeneration (wet AMD). The program includes two trials, COAST and ShORe, enrolling 1,984 patients combined. These trials aim to replicate the superior visual outcomes demonstrated in the Phase 2b study. Topline data is anticipated by mid-2025. The trials will compare the efficacy and safety of sozinibercept combined with standard anti-VEGF-A therapies against standard care alone. The primary endpoint is the mean change in Best Corrected Visual Acuity (BCVA) over 52 weeks, with ongoing safety evaluations for up to two years.
Opthea (OPT) announced its participation in the Retina World Congress 2024 to present scientific updates on sozinibercept (OPT-302) Phase 2 trial results and Phase 3 program. CEO Frederic Guerard and other key professionals will discuss the latest advancements in wet age-related macular degeneration treatment.
FAQ
What is the current stock price of Opthea (OPT)?
What is the market cap of Opthea (OPT)?
